RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

Glucotrack calls its device, which has no external on-body component, a continuous blood glucose monitor (CBGM). The implant is around the length and thickness of three US nickels, with a total ...

This milestone study, which aimed to evaluate the safety of the implant, use, and removal of the CBGM sensor lead, confirms the potential of this novel technology. The prospective study was ...

For more information about Glucotrack's CBGM, visit glucotrack.com . Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.

This study represents first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the ...

ISO 13485 is also strongly recommended and widely used in the European Union. For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not ...

Glucotrack, Inc. has announced the successful completion of its first human clinical study for a continuous blood glucose monitor (CBGM), which is uniquely placed in the subclavian vein for real ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...